Drug Trial Radar · NCT07222189
A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
7
Actual
Start
May 19, 2026
Primary completion
Sep 29, 2026
Study completion Oct 15, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 77 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week treatment period (on balinatunfib or placebo) in the parent studies, SPECIFI-CD (DRI18212) or SPECIFI-UC (DRI17822), respectively. * The primary objective of this study is to assess the long-term safety and tolerability of different doses of balinatunfib in participants with CD or UC, as measured by the number and percentage of participants with CD or UC with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) during the study period. * The study will consist of 2 independent cohorts through the study given the distinct nature of each disease: * CD Cohort: comprised of CD participants enrolled from SPECIFI-CD (DRI18212). * UC Cohort: comprised of UC participants enrolled from SPECIFI-UC (DRI17822). * The study will consist of the following study periods for each cohort: * A Double-Blind (DB) treatment period of up to 104 weeks for eligible participants from the DB maintenance phases of the respective parent studies. * An Open-Label (OL) treatment period of up to 104 weeks for: * Eligible participants from either the DB or OL periods of the parent studies, * Eligible participants who meet escape criteria at any time during the DB period of the LTS19689. * A 2-week follow-up period following the End of Treatment (EOT). The study duration will be up to 107 weeks, with the treatment duration up to 104 weeks.
Conditions
- Colitis Ulcerative
- Crohn's Disease
Interventions
balinatunfibDrug
Pharmaceutical form:Tablet -Route of administration:Oral
balinatunfib-matching placeboDrug
Pharmaceutical form:Tablet -Route of administration:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Crohn's Disease with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: Up to End of Study (approximately 106 weeks)
- Number of participants with ulcerative colitis with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: Up to End of Study (approximately 106 weeks)
Locations
10 sites in 7 countries. Site status is shown where the registry gives one.
Texas Digestive Disease Consultants - Southlake- Site Number : 8400005
Southlake, Texas
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 1000001
Gorna Oryahovitsa, Bulgaria
Investigational Site Number : 1520016
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520010
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520012
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1560002
Guangzhou, China
Investigational Site Number : 1560032
Shanghai, China
Investigational Site Number : 2030001
Olomouc, Czechia
Investigational Site Number : 3800002
Milan, Milano, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.